Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2010

01-04-2010 | Preclinical study

The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding

Authors: Stefania Millevoi, Sandra Bernat, Dominique Telly, Françoise Fouque, Laurence Gladieff, Gilles Favre, Stéphan Vagner, Christine Toulas

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Login to get access

Abstract

Several unclassified variants (UV) of BRCA1 can be deleterious by affecting normal pre-mRNA splicing. Here, we investigated the consequences at the mRNA level of the frequently encountered c.5242C>A UV in BRCA1 exon 18. We show that the c.5242C>A variant induces skipping of exon 18 in UV carriers and in vitro. This alteration predicted to disrupt the first BRCT domain of BRCA1. We show that two splicing repressors, hnRNP A1 and hnRNP H/F, display a significant preference toward binding with the mutated exon 18 and assemble into a protein complex. Sequence analysis of the region surrounding the c.5242C>A change reveals the presence of hnRNP A1 and hnRNP H/F binding sites, which are modified by several UVs. Mutation of these sites alters the RNA binding ability of both splicing regulators. In conclusion, our work supports the model of the pathogenicity of the c.5242C>A BRCA1 variant that induces exon skipping by creating a sequence with silencer properties. We propose that other UVs in exon 18 interfere with splicing complex assembly by perturbing the binding of hnRNP A1 and hnRNP H/F to their respective cis-elements. RNA analysis is therefore necessary for the assessment of the consequences of UVs on splicing of disease-associated genes and to enable adequate genetic counseling for breast/ovarian cancer families.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mazoyer S, Puget N, Perrin-Vidoz L et al (1998) A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet 62:713–715CrossRefPubMed Mazoyer S, Puget N, Perrin-Vidoz L et al (1998) A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet 62:713–715CrossRefPubMed
2.
go back to reference Liu HX, Cartegni L, Zhang MQ et al (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27:55–58PubMed Liu HX, Cartegni L, Zhang MQ et al (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27:55–58PubMed
3.
go back to reference Kashima T, Rao N, David CJ et al (2007) hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet 16:3149–3159CrossRefPubMed Kashima T, Rao N, David CJ et al (2007) hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet 16:3149–3159CrossRefPubMed
4.
go back to reference Goina E, Skoko N, Pagani F (2008) Binding of DAZAP1 and hnRNPA1/A2 to an exonic splicing silencer in a natural BRCA1 exon 18 mutant. Mol Cell Biol 28:3850–3860CrossRefPubMed Goina E, Skoko N, Pagani F (2008) Binding of DAZAP1 and hnRNPA1/A2 to an exonic splicing silencer in a natural BRCA1 exon 18 mutant. Mol Cell Biol 28:3850–3860CrossRefPubMed
5.
go back to reference Vallon-Christersson J, Cayanan C, Haraldsson K et al (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353–360CrossRefPubMed Vallon-Christersson J, Cayanan C, Haraldsson K et al (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353–360CrossRefPubMed
6.
go back to reference Lovelock PK, Healey S, Au W et al (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43:74–83CrossRefPubMed Lovelock PK, Healey S, Au W et al (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43:74–83CrossRefPubMed
7.
go back to reference Mayeda A, Krainer AR (1999) Preparation of HeLa cell nuclear and cytosolic S100 extracts for in vitro splicing. Methods Mol Biol 118:309–314PubMed Mayeda A, Krainer AR (1999) Preparation of HeLa cell nuclear and cytosolic S100 extracts for in vitro splicing. Methods Mol Biol 118:309–314PubMed
8.
go back to reference Cartegni L, Krainer AR (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30:377–384CrossRefPubMed Cartegni L, Krainer AR (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30:377–384CrossRefPubMed
9.
go back to reference Millevoi S, Loulergue C, Dettwiler S et al (2006) An interaction between U2AF 65 and CF I(m) links the splicing and 3′ end processing machineries. EMBO J 25:4854–4864CrossRefPubMed Millevoi S, Loulergue C, Dettwiler S et al (2006) An interaction between U2AF 65 and CF I(m) links the splicing and 3′ end processing machineries. EMBO J 25:4854–4864CrossRefPubMed
10.
go back to reference Cammas A, Pileur F, Bonnal S et al (2007) Cytoplasmic relocalization of heterogeneous nuclear ribonucleoprotein A1 controls translation initiation of specific mRNAs. Mol Biol Cell 18:5048–5059CrossRefPubMed Cammas A, Pileur F, Bonnal S et al (2007) Cytoplasmic relocalization of heterogeneous nuclear ribonucleoprotein A1 controls translation initiation of specific mRNAs. Mol Biol Cell 18:5048–5059CrossRefPubMed
11.
go back to reference Zheng ZM, Huynen M, Baker CC (1998) A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly. Proc Natl Acad Sci U S A 95:14088–14093CrossRefPubMed Zheng ZM, Huynen M, Baker CC (1998) A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly. Proc Natl Acad Sci U S A 95:14088–14093CrossRefPubMed
12.
go back to reference Masuyama K, Taniguchi I, Okawa K et al (2007) Factors associated with a purine-rich exonic splicing enhancer sequence in Xenopus oocyte nucleus. Biochem Biophys Res Commun 359:580–585CrossRefPubMed Masuyama K, Taniguchi I, Okawa K et al (2007) Factors associated with a purine-rich exonic splicing enhancer sequence in Xenopus oocyte nucleus. Biochem Biophys Res Commun 359:580–585CrossRefPubMed
13.
go back to reference Spellman R, Smith CW (2006) Novel modes of splicing repression by PTB. Trends Biochem Sci 31:73–76CrossRefPubMed Spellman R, Smith CW (2006) Novel modes of splicing repression by PTB. Trends Biochem Sci 31:73–76CrossRefPubMed
14.
go back to reference Kim JH, Hahm B, Kim YK et al (2000) Protein–protein interaction among hnRNPs shuttling between nucleus and cytoplasm. J Mol Biol 298:395–405CrossRefPubMed Kim JH, Hahm B, Kim YK et al (2000) Protein–protein interaction among hnRNPs shuttling between nucleus and cytoplasm. J Mol Biol 298:395–405CrossRefPubMed
15.
go back to reference Expert-Bezancon A, Sureau A, Durosay P et al (2004) hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B. J Biol Chem 279:38249–38259CrossRefPubMed Expert-Bezancon A, Sureau A, Durosay P et al (2004) hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B. J Biol Chem 279:38249–38259CrossRefPubMed
16.
go back to reference Guil S, Gattoni R, Carrascal M et al (2003) Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation. Mol Cell Biol 23:2927–2941CrossRefPubMed Guil S, Gattoni R, Carrascal M et al (2003) Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation. Mol Cell Biol 23:2927–2941CrossRefPubMed
17.
go back to reference Caputi M, Zahler AM (2001) Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H′/F/2H9 family. J Biol Chem 276:43850–43859CrossRefPubMed Caputi M, Zahler AM (2001) Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H′/F/2H9 family. J Biol Chem 276:43850–43859CrossRefPubMed
18.
go back to reference Cantor SB, Bell DW, Ganesan S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149–160CrossRefPubMed Cantor SB, Bell DW, Ganesan S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149–160CrossRefPubMed
19.
20.
go back to reference Lovelock PK, Spurdle AB, Mok MT et al (2007) Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9:R82CrossRefPubMed Lovelock PK, Spurdle AB, Mok MT et al (2007) Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9:R82CrossRefPubMed
21.
go back to reference Mirkovic N, Marti-Renom MA, Weber BL et al (2004) Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64:3790–3797CrossRefPubMed Mirkovic N, Marti-Renom MA, Weber BL et al (2004) Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64:3790–3797CrossRefPubMed
22.
go back to reference Kawai H, Li H, Chun P et al (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21:7730–7739CrossRefPubMed Kawai H, Li H, Chun P et al (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21:7730–7739CrossRefPubMed
23.
go back to reference Williams RS, Green R, Glover JN (2001) Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8:838–842CrossRefPubMed Williams RS, Green R, Glover JN (2001) Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8:838–842CrossRefPubMed
24.
go back to reference Schaub MC, Lopez SR, Caputi M (2007) Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes. J Biol Chem 282:13617–13626CrossRefPubMed Schaub MC, Lopez SR, Caputi M (2007) Members of the heterogeneous nuclear ribonucleoprotein H family activate splicing of an HIV-1 splicing substrate by promoting formation of ATP-dependent spliceosomal complexes. J Biol Chem 282:13617–13626CrossRefPubMed
25.
go back to reference Burd CG, Dreyfuss G (1994) RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J 13:1197–1204PubMed Burd CG, Dreyfuss G (1994) RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J 13:1197–1204PubMed
26.
go back to reference Zhu J, Mayeda A, Krainer AR (2001) Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell 8:1351–1361CrossRefPubMed Zhu J, Mayeda A, Krainer AR (2001) Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell 8:1351–1361CrossRefPubMed
27.
go back to reference Auclair J, Busine MP, Navarro C et al (2006) Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat 27:145–154CrossRefPubMed Auclair J, Busine MP, Navarro C et al (2006) Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat 27:145–154CrossRefPubMed
28.
go back to reference Houdayer C, Dehainault C, Mattler C et al (2008) Evaluation of in silico splice tools for decision-making in molecular diagnosis. Hum Mutat 29:975–982CrossRefPubMed Houdayer C, Dehainault C, Mattler C et al (2008) Evaluation of in silico splice tools for decision-making in molecular diagnosis. Hum Mutat 29:975–982CrossRefPubMed
29.
go back to reference Lastella P, Surdo NC, Resta N et al (2006) In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 7:243CrossRefPubMed Lastella P, Surdo NC, Resta N et al (2006) In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 7:243CrossRefPubMed
Metadata
Title
The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding
Authors
Stefania Millevoi
Sandra Bernat
Dominique Telly
Françoise Fouque
Laurence Gladieff
Gilles Favre
Stéphan Vagner
Christine Toulas
Publication date
01-04-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0392-3

Other articles of this Issue 2/2010

Breast Cancer Research and Treatment 2/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine